MarketScanners

Message Follow Following Unfollow
Last visit Joined 4 years ago marketscanners
Markets Allocation
100 % stocks
Top Mentioned Symbols
LOCM 28% | 2 ARQL 28% | 2 MEIP 14% | 1 EXEL 14% | 1
MarketScanners MarketScanners ARQL, W, Long , 3 years ago
ARQL: ARQL Short Squeeze Set-Up
192 0 1
ARQL, W Long
ARQL Short Squeeze Set-Up
Upcoming catalyst could cause these shares to double. See: http://www.benzinga.com/pressreleases/12/12/tr3182627/arqule-arql-poised-for-a-quick-move-up-on-near-term-catalyst
MarketScanners MarketScanners ARQL, W, Long , 3 years ago
ARQL: ARQL Ready Break Out Past Resistance
233 0 0
ARQL, W Long
ARQL Ready Break Out Past Resistance
All it takes is a little volume and upcoming catalysts should provide that. See: http://www.biomedreports.com/20121218116847/arqule-a-strong-speculative-biopharma-poised-for-a-quick-move-up-on-near-term-catalyst.html
MarketScanners MarketScanners MDGN, W, Long , 4 years ago
MDGN: Biotech Breakout
131 0 0
MDGN, W Long
Biotech Breakout
low float mdgn shares breaking out- upcoming clinical catalysts should help push.
MarketScanners MarketScanners MEIP, D, Long , 4 years ago
MEIP: MEIP Catalyst Trade With Technical Set-Up
224 0 0
MEIP, D Long
MEIP Catalyst Trade With Technical Set-Up
MEI Pharma, Inc. (MEIP), will be presenting data on Pracinostat, in combination with azacitidine in patients with advanced myelodysplastic syndrome (MDS) at a poster presentation at the American Society of Hematology Annual Meeting on December 10, 2012. Stock looks good for at least a $.50 pop
MarketScanners MarketScanners LOCM, D, Long , 4 years ago
LOCM: This one set to move on IP news!
170 0 1
LOCM, D Long
This one set to move on IP news!
Our search through databases at the United States Patent and Trademark Office appear to show that Local was recently granted a U.S. patent to further monetize the $2.7 Billion mobile advertising market. Monetizing mobile is big and investors are following who owns the IP real estate in this market. This patent ...
MarketScanners MarketScanners EXEL, D, Long , 4 years ago
EXEL: EXEL Climbing Ahead of FDA Decision
138 0 0
EXEL, D Long
EXEL Climbing Ahead of FDA Decision
$EXEL shares starting to break-out.FDA decision scheduled to Nov. 29. "optimists like cabozantinib's chances for approval" says Motley Fool. Looks like negative over-all market conditions weighing in on the stock move. Watch this one! ...
MarketScanners MarketScanners LOCM, D, Long , 4 years ago
LOCM: Breakout for LOCM
141 0 0
LOCM, D Long
Breakout for LOCM
LOCM shares appear to be breaking out. Pending news and any influx of volume could really push shares much higher here. There appears to be very little overhang here as the stock trades very freely. Fundamentally, the stock appears to be undervalued as well, so we see this as a big upside/low risk trade. $LOCM
lukelehepuu.com/etoroinfo.profile.website }}
Message Follow Following Unfollow
India iFxsaint
Message Follow Following Unfollow
USA tradingview.cominfo.profile.website }} tradingview
Message Follow Following Unfollow
Message Follow Following Unfollow
Message Follow Following Unfollow
Message Follow Following Unfollow
Message Follow Following Unfollow
Message Follow Following Unfollow
Message Follow Following Unfollow
Message Follow Following Unfollow
Message Follow Following Unfollow
Message Follow Following Unfollow
Message Follow Following Unfollow
Message Follow Following Unfollow
Message Follow Following Unfollow
Message Follow Following Unfollow
Message Follow Following Unfollow
Message Follow Following Unfollow
Message Follow Following Unfollow
Message Follow Following Unfollow
User follows nobody
User has no following symbols
Market
Interval
Browse
Time
Type
Browse
Time
Ideas Scripts Chart
United States
United Kingdom
India
España
Italia
Brasil
Россия
Türkiye
日本
한국
Home Stock Screener Economic Calendar How It Works Chart Features House Rules Moderators For the WEB Widgets Stock Charting Library Priority Support Feature Request Blog & News FAQ Help & Wiki Twitter
Private Messages Chat Ideas Published Followers Following Priority Support Public Profile Profile Settings Billing Sign Out